- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02403037
Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients
The Effects of Auricular Acupressure on Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients: A Pilot Randomized Controlled Trial
To evaluate the feasibility of a three-parallel-arm, placebo-controlled randomized trial using a standard auricular acupressure protocol for managing nausea and vomiting in a homogenous group of female breast cancer patients undergoing chemotherapy.
The null hypotheses of this study are: (1) There will be no significant difference in acute/delayed nausea and vomiting among groups during the intervention period; (2) There will be no significant difference in anticipatory nausea and vomiting among groups before the second cycle of chemotherapy; (3) There will be no significant difference in quality of life status among groups at the end of the first cycle of chemotherapy.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and distressing side-effects among cancer patients undergoing chemotherapy. Despite steady progresses in antiemetic prophylaxis and treatment during the past decades, approximately half of cancer patients receiving moderately to highly emetogenic chemotherapy still experience significant nausea and vomiting. Considering the facts that CINV is difficult to be completely controlled by antiemetics along, healthcare professionals has explored the role of non-pharmacological interventions as adjunctive therapy for controlling CINV. Among which, auricular therapy (AT) is a promising approach but the evidence has still not been concluded.
The aim of this study is to test the feasibility of a randomized controlled trial using auricular acupressure protocol for managing nausea and vomiting in female breast cancer patients undergoing chemotherapy. The objectives of this study will be: (1) to pilot the methodological procedure of the randomized controlled trial using a standard auricular acupressure protocol for controlling CINV; (2) to determine the recruitment rate and attrition rate during the whole study period; (3) to determine the feasibility of the study questionnaires and auricular acupressure protocol to the study participants; (4) to identify potential adverse events associated with auricular acupressure; (5) to preliminarily examine the effects of auricular acupressure on CINV and QoL in female breast cancer patients receiving chemotherapy; (6) to explore patients' experience in completing the trial and receiving the intervention; and (7) to refine the study protocol for a future multicenter, large-scale randomized controlled trial.
A three-parallel-arm, placebo-controlled randomized pilot study will be adopted. One hundred and fourteen breast cancer patients scheduled to receive the first cycle of chemotherapy will be recruited from three provincial hospitals in Fuzhou, China, and will be randomly assigned to one of the three groups: the true AT group, the sham AT group or the standard care group. Participants in the true AT group will receive standard anti-emetic medications plus a 5-day auricular acupressure at the specific ear acupoints, participants in the sham AT group will receive standard anti-emetic medications plus a 5-day auricular acupressure at the same acupoints as in the true AT group without any acupoint stimulation, while participants in the standard care group will only be provided with the standard anti-emetic medications. The feasibility outcomes will be the recruitment rate and consent rate during the recruitment stage, the attrition rate during the whole study period, feasibility of the study questionnaires and auricular acupressure protocol to the study participants, and AT-related adverse events. The future main study outcomes will also be measured including acuteCINV, delayed CINV, anticipatory CINV, and quality of life. After completing the pilot clinical trial, a nested qualitative interview will be conducted to explore participants' experience in completing the trial and receiving the intervention.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Fujian
-
Fuzhou, Fujian, Chine, 350014
- Fujian Provincial Cancer Hospital
-
Fuzhou, Fujian, Chine, 350003
- The Second People's Hospital of Fujian Province
-
Fuzhou, Fujian, Chine, 350004
- The First People's Hospital of Fujian Province
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adult female patients aged above 18 years old;
- A diagnosis of breast cancer stage I-III;
- Chemotherapy- naive;
- Auricular therapy-naive;
- Be able to communicate in Chinese mandarin;
- Have at least completed a primary school education;
- Agree to participate in the study and be willing to give written informed consent;
- Be scheduled to receive the first cycle of chemotherapy with moderately-high to highly emetogenic potentials;
- Be provided with standard antiemetic medications during chemotherapy.
Exclusion Criteria:
- Extremely weak, disabled or immunocompromised cancer patients;
- Be unable to follow the study instructions to do AT intervention or other research procedures;
- Have concurrent radiotherapy or other kinds of antineoplastic therapy;
- Currently take part in clinical studies on anti-emetic medications or other kinds of non-pharmacological interventions to control CINV, or other studies which are believed to produce potential interactions with this AT trial;
- Have other health problems which may affect the symptoms of CINV such as gastrointestinal disease, liver disease, migraine, tinnitus and Ménière's disease, etc.;
- Ear skin problems which are not appropriate for auricular acupressure including ear infections, ear scars and rashes, ear frostbite, and ear abscess, etc.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: True Auricular Acupressure Group
Participants in this group will receive standard antiemetics before and during chemotherapy, and a 5-day auricular acupressure treatment protocol for controlling nausea and vomiting during the first cycle of chemotherapy.
|
A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
Autres noms:
5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
Autres noms:
|
Comparateur factice: Sham Auricular Acupressure Group
Participants in this group will receive standard antiemetic medications before and during chemotherapy, and a 5-day sham auricular acupressure intervention protocol during the first cycle of chemotherapy.
|
5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
Autres noms:
A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
Autres noms:
|
Autre: Standard Care Group
Participants in this group will only receive standard anti-emetic treatment before and during chemotherapy.
|
5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Recruitment Rate
Délai: Through study completion, an average of 1 year and 4 months
|
Feasibility outcome
|
Through study completion, an average of 1 year and 4 months
|
Consent Rate
Délai: Through study completion, an average of 1 year and 4 months
|
Feasibility outcome
|
Through study completion, an average of 1 year and 4 months
|
Attrition Rate
Délai: Through study completion, an average of 1 year and 4 months
|
Feasibility outcome
|
Through study completion, an average of 1 year and 4 months
|
Feasibility of the Study Questionnaires and Auricular Acupressure Protocol
Délai: Through study completion, an average of 1 year and 4 months
|
Feasibility outcome
|
Through study completion, an average of 1 year and 4 months
|
Potential Adverse Events associated with Auricular Acupressure
Délai: During the 5-day intervention period
|
Feasibility outcome
|
During the 5-day intervention period
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Occurrence of Acute Vomiting
Délai: The 2nd day of the first chemotherapy cycle
|
Secondary outcome
|
The 2nd day of the first chemotherapy cycle
|
Frequency of Acute Vomiting
Délai: The 2nd day of the first chemotherapy cycle
|
Secondary outcome
|
The 2nd day of the first chemotherapy cycle
|
Occurrence of Acute Nausea
Délai: The 2nd day of the first chemotherapy cycle
|
Secondary outcome
|
The 2nd day of the first chemotherapy cycle
|
Severity of Acute Nausea
Délai: The 2nd day of the first chemotherapy cycle
|
Secondary outcome
|
The 2nd day of the first chemotherapy cycle
|
Occurrence of Delayed Vomiting
Délai: The 6th day of the first chemotherapy cycle
|
Secondary outcome
|
The 6th day of the first chemotherapy cycle
|
Frequency of Delayed Vomiting
Délai: The 6th day of the first chemotherapy cycle
|
Secondary outcome
|
The 6th day of the first chemotherapy cycle
|
Occurrence of Delayed Nausea
Délai: The 6th day of the first chemotherapy cycle
|
Secondary outcome
|
The 6th day of the first chemotherapy cycle
|
Severity of Delayed Nausea
Délai: The 6th day of the first chemotherapy cycle
|
Secondary outcome
|
The 6th day of the first chemotherapy cycle
|
Anticipatory Nausea and Vomiting
Délai: The 1st day of the second chemotherapy cycle
|
The measure is a composite
|
The 1st day of the second chemotherapy cycle
|
Quality of Life Status
Délai: The 21st day of the first chemotherapy cycle
|
Secondary outcome
|
The 21st day of the first chemotherapy cycle
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Lorna SUEN, PhD, The Hong Kong Polytechnic University
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies de la peau
- Tumeurs
- Tumeurs par site
- Signes et symptômes digestifs
- Maladies du sein
- Tumeurs mammaires
- Nausée
- Vomissement
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents autonomes
- Agents du système nerveux périphérique
- Inhibiteurs d'enzymes
- Agents anti-inflammatoires
- Agents antinéoplasiques
- Agents gastro-intestinaux
- Glucocorticoïdes
- Les hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Agents antinéoplasiques, hormonaux
- Inhibiteurs de protéase
- Dexaméthasone
- Acétate de dexaméthasone
- BB 1101
- Antiémétiques
- Émétique
Autres numéros d'identification d'étude
- HSEARS20150213001
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Tumeurs mammaires
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
Essais cliniques sur True auricular acupressure
-
Shanghai General Hospital, Shanghai Jiao Tong University...Duke University; Rutgers University; Tsinghua UniversityComplétéNon-fumeurs, Adultes en bonne santéChine
-
C. R. BardComplétéSténose valvulaire aortiqueAllemagne
-
Procter and GambleComplété
-
The Hong Kong Polytechnic UniversityComplété
-
University of the Incarnate WordInscription sur invitationIntolérance alimentaireÉtats-Unis
-
AllerdermComplétéDermatite de contactÉtats-Unis
-
Adam Howe, MDLitholinkComplétéEn bonne santéÉtats-Unis